Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: stocktwits
- Licensing Agreement Details: Travere Therapeutics has entered into a licensing agreement with China's Everest Medicines, paying $112.5 million upfront for exclusive rights to develop and sell Civorebrutinib in the U.S. and other markets, which is expected to significantly enhance its market position in rare kidney disease treatments.
- Optimistic Clinical Outlook: Early clinical studies indicate that Civorebrutinib effectively lowers harmful antibodies and excess protein in urine, helps more patients achieve remission, and maintains stable kidney function for up to a year, showcasing its potential to become a 'best-in-class' treatment.
- Positive Market Reaction: Although Travere's stock initially fell 6% following the announcement, H.C. Wainwright raised its price target from $57 to $67, implying a potential upside of 49%, reflecting market optimism regarding the drug's prospects.
- Future Research Plans: Travere plans to further study Civorebrutinib in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with potential milestone payments of up to $1.03 billion and ongoing royalties if the drug successfully reaches the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to fall
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 54.140
Low
31.00
Averages
42.89
High
49.00
Current: 54.140
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Leadership Transition at Travere Therapeutics
- Executive Retirement Plan: William Rote, Ph.D., the Chief Research Officer of Travere Therapeutics, plans to retire in February 2027 after a decade of service, marking a significant leadership transition that may impact the company's R&D direction.
- Expanded Responsibilities for Inrig: Jula Inrig, M.D., will be appointed as Executive Vice President, Head of Research and Development, and CMO, expanding her role to include the company's research organization, which is expected to drive further advancements in the rare disease sector.
- Enhanced R&D Capabilities: During his tenure, Dr. Rote successfully facilitated approvals for IgA nephropathy and focal segmental glomerulosclerosis, establishing the company as a leader in rare diseases, while Dr. Inrig's appointment is anticipated to strengthen this position further.
- Strategic Collaboration and Transition: Dr. Rote expressed his commitment to working closely with Dr. Inrig to ensure a smooth transition, reflecting the company's dedication to ongoing innovation and patient service, which may lay the groundwork for future R&D initiatives.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On June 10, 2026, Travere Therapeutics granted 32,000 restricted stock units (RSUs) to six new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were awarded under Travere's 2018 Equity Incentive Plan, although granted outside of it, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to new hires.
- Vesting Arrangement: The RSUs vest over four years, with 25% vesting annually, which not only incentivizes long-term employee retention but also ensures ongoing contributions during their service with the company.
- Company Mission: Travere Therapeutics is dedicated to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, showcasing the company's deep commitment to patient care.
See More
Long-term Results of FILSPARI Show Significant Efficacy
- Efficacy Durability: In a five-year study, patients treated with FILSPARI maintained durable reductions in proteinuria, achieving clinically meaningful low proteinuria thresholds, demonstrating the drug's long-term effectiveness in treating FSGS.
- Rapid Transition Effects: Patients transitioning from maximum labeled dose irbesartan to FILSPARI during the open-label extension experienced rapid and sustained reductions in proteinuria, indicating that FILSPARI's efficacy is comparable to those who initiated treatment during the double-blind period, reinforcing its role as foundational care.
- Clinical Outcome Superiority: At the end of the double-blind period, the complete remission rate for FILSPARI patients was 18.5% compared to 7.5% for irbesartan, with partial remission rates of 69.0% and 50.8%, respectively, highlighting FILSPARI's significant advantages in treating FSGS.
- Good Safety Profile: Over five years of follow-up, FILSPARI was generally well tolerated, with a safety profile consistent with previous findings, further enhancing confidence in its clinical application.
See More
Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
- Licensing Agreement Details: Travere Therapeutics has entered into a licensing agreement with China's Everest Medicines, paying $112.5 million upfront for exclusive rights to develop and sell Civorebrutinib in the U.S. and other markets, which is expected to significantly enhance its market position in rare kidney disease treatments.
- Optimistic Clinical Outlook: Early clinical studies indicate that Civorebrutinib effectively lowers harmful antibodies and excess protein in urine, helps more patients achieve remission, and maintains stable kidney function for up to a year, showcasing its potential to become a 'best-in-class' treatment.
- Positive Market Reaction: Although Travere's stock initially fell 6% following the announcement, H.C. Wainwright raised its price target from $57 to $67, implying a potential upside of 49%, reflecting market optimism regarding the drug's prospects.
- Future Research Plans: Travere plans to further study Civorebrutinib in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with potential milestone payments of up to $1.03 billion and ongoing royalties if the drug successfully reaches the market.
See More
Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement
- Agreement Details: Travere Therapeutics (TVTX) has entered into a licensing and collaboration agreement worth up to $1.1 billion with China's Everest Medicines, securing exclusive development and commercialization rights for civorebrutinib, aimed at rare immune-mediated kidney diseases, highlighting the company's strategic expansion in the biopharma sector.
- Upfront and Milestone Payments: Under the terms, Travere will receive $112.5 million upfront and up to $1.03 billion in milestone payments, providing substantial funding for R&D efforts and advancing civorebrutinib across five indications.
- Market Potential and Royalties: Everest Medicines will be eligible for tiered royalties ranging from high single-digit to double-digit percentages based on future sales, ensuring a revenue stream that could foster further collaboration in other markets.
- US-China Collaboration Trend: Despite geopolitical tensions, U.S. biopharma companies are increasingly pursuing licensing deals with China, reflecting confidence in the Chinese biopharma market and the potential for mutual growth opportunities.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
Leadership Transition at Travere Therapeutics
- Executive Retirement Plan: William Rote, Ph.D., the Chief Research Officer of Travere Therapeutics, plans to retire in February 2027 after a decade of service, marking a significant leadership transition that may impact the company's R&D direction.
- Expanded Responsibilities for Inrig: Jula Inrig, M.D., will be appointed as Executive Vice President, Head of Research and Development, and CMO, expanding her role to include the company's research organization, which is expected to drive further advancements in the rare disease sector.
- Enhanced R&D Capabilities: During his tenure, Dr. Rote successfully facilitated approvals for IgA nephropathy and focal segmental glomerulosclerosis, establishing the company as a leader in rare diseases, while Dr. Inrig's appointment is anticipated to strengthen this position further.
- Strategic Collaboration and Transition: Dr. Rote expressed his commitment to working closely with Dr. Inrig to ensure a smooth transition, reflecting the company's dedication to ongoing innovation and patient service, which may lay the groundwork for future R&D initiatives.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On June 10, 2026, Travere Therapeutics granted 32,000 restricted stock units (RSUs) to six new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were awarded under Travere's 2018 Equity Incentive Plan, although granted outside of it, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to new hires.
- Vesting Arrangement: The RSUs vest over four years, with 25% vesting annually, which not only incentivizes long-term employee retention but also ensures ongoing contributions during their service with the company.
- Company Mission: Travere Therapeutics is dedicated to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, showcasing the company's deep commitment to patient care.
See More
Long-term Results of FILSPARI Show Significant Efficacy
- Efficacy Durability: In a five-year study, patients treated with FILSPARI maintained durable reductions in proteinuria, achieving clinically meaningful low proteinuria thresholds, demonstrating the drug's long-term effectiveness in treating FSGS.
- Rapid Transition Effects: Patients transitioning from maximum labeled dose irbesartan to FILSPARI during the open-label extension experienced rapid and sustained reductions in proteinuria, indicating that FILSPARI's efficacy is comparable to those who initiated treatment during the double-blind period, reinforcing its role as foundational care.
- Clinical Outcome Superiority: At the end of the double-blind period, the complete remission rate for FILSPARI patients was 18.5% compared to 7.5% for irbesartan, with partial remission rates of 69.0% and 50.8%, respectively, highlighting FILSPARI's significant advantages in treating FSGS.
- Good Safety Profile: Over five years of follow-up, FILSPARI was generally well tolerated, with a safety profile consistent with previous findings, further enhancing confidence in its clinical application.
See More
Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
- Licensing Agreement Details: Travere Therapeutics has entered into a licensing agreement with China's Everest Medicines, paying $112.5 million upfront for exclusive rights to develop and sell Civorebrutinib in the U.S. and other markets, which is expected to significantly enhance its market position in rare kidney disease treatments.
- Optimistic Clinical Outlook: Early clinical studies indicate that Civorebrutinib effectively lowers harmful antibodies and excess protein in urine, helps more patients achieve remission, and maintains stable kidney function for up to a year, showcasing its potential to become a 'best-in-class' treatment.
- Positive Market Reaction: Although Travere's stock initially fell 6% following the announcement, H.C. Wainwright raised its price target from $57 to $67, implying a potential upside of 49%, reflecting market optimism regarding the drug's prospects.
- Future Research Plans: Travere plans to further study Civorebrutinib in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with potential milestone payments of up to $1.03 billion and ongoing royalties if the drug successfully reaches the market.
See More
Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement
- Agreement Details: Travere Therapeutics (TVTX) has entered into a licensing and collaboration agreement worth up to $1.1 billion with China's Everest Medicines, securing exclusive development and commercialization rights for civorebrutinib, aimed at rare immune-mediated kidney diseases, highlighting the company's strategic expansion in the biopharma sector.
- Upfront and Milestone Payments: Under the terms, Travere will receive $112.5 million upfront and up to $1.03 billion in milestone payments, providing substantial funding for R&D efforts and advancing civorebrutinib across five indications.
- Market Potential and Royalties: Everest Medicines will be eligible for tiered royalties ranging from high single-digit to double-digit percentages based on future sales, ensuring a revenue stream that could foster further collaboration in other markets.
- US-China Collaboration Trend: Despite geopolitical tensions, U.S. biopharma companies are increasingly pursuing licensing deals with China, reflecting confidence in the Chinese biopharma market and the potential for mutual growth opportunities.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
